Global Pharmatech, Inc. engages in the discovery, development, manufacturing, and marketing of proprietary drugs developed based on traditional Chinese medicine. The company is headquartered in Changchun, Jilin and currently employs 217 full-time employees. The company went IPO on 2006-05-12. The Company’s main patented products include JUTAI SOFT CAPSULE, QINGXUAN ANTI-HYPERTENSION TABLET, YANREQING TABLET. The firm is also engaged in the manufacture and sales of other proprietary drugs, generics and dietary supplements used to treat symptoms ranging from headaches, coughing and dry mouth to infections and numbness of limbs. The firm also engages in the provision of biotechnology services, including research and development, testing, manufacturing drugs in liquid and solid dose forms, sales and marketing. The firm conducts its business in the domestic and overseas markets.
최신 재무제표(Form-10K)에 따르면, Global Pharmatech Inc의 총 자산은 $13이며, 순손실입니다.
GBLP의 주요 재무 비율은 무엇인가요?
Global Pharmatech Inc의 유동비율은 2.6이고, 순이익률은 -150, 주당 매출은 $0.08입니다.
Global Pharmatech Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Global Pharmatech Inc 주요 수익원은 Botanical Extracts/Herbal Extracts and Herbal Formulations이며, 최신 수익 발표에서 수익은 310,895입니다. 지역별로는 China이 Global Pharmatech Inc의 주요 시장이며, 수익은 310,895입니다.
Global Pharmatech Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Global Pharmatech Inc의 순손실은 $-3입니다.